Tech Company Financing Transactions
BioClin Therapeutics Funding Round
On 5/10/2018, BioClin Therapeutics landed $50 million in Series B funding from Healthcap Venture Capital, INKEF Capital and Life Sciences Partners.
Transaction Overview
Company Name
Announced On
5/10/2018
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series B
Investors
Sofinnova Ventures (David Kabakoff)
Ysios Capital (Joël Jean-Mairet)
Proceeds Purpose
The proceeds from this financing will be used to advance the company's lead development candidate, B-701, for the treatment of patients with metastatic bladder cancer, or metastatic urothelial carcinoma (mUC).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1040 Davis St. 202
San Leandro, CA 94577
USA
San Leandro, CA 94577
USA
Phone
Website
Email Address
Overview
Our strategy is to develop biologics for medical conditions where there has been no approved or satisfactory therapy. Our lead product, B-701, is a human antibody targeting FGFR3 (fibroblast growth factor receptor 3) being developed as a treatment for metastatic bladder cancer and achondroplasia (dwarfism).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Stephen Lau
Chief Medical Officer
Steve Abella
Chief Operating Officer
Graeme Currie
VP - Finance
Guy Shields
VP - Manufacturing
Eric Emery
VP - Operations
Isagani Cornelio
Browse more venture capital transactions:
Prev: 5/10/2018: Drishti venture capital transaction
Next: 5/10/2018: ClickFox venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on all VC transactions involving tech companies. VC transactions reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs